FDA approves efficacy supplement for Teva's Igalmi
The FDA cleared a third supplemental application for the dexmedetomidine film Igalmi, with a new label dated November 16, 2026.
Drugs@FDA
13 stories
The FDA cleared a third supplemental application for the dexmedetomidine film Igalmi, with a new label dated November 16, 2026.
Drugs@FDA
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Teva's board elected Dr. David J. Brailer as a new independent director effective November 3, 2026, following an October 27 board meeting.
SEC filing
Teva Pharmaceuticals, Inc. won approval for Degevma (denosumab-adet), a subcutaneous injectable, under BLA 761481.
Drugs@FDA
Teva Pharmaceutical Finance units issued five tranches of notes on September 16, 2026, with proceeds set to fund redemptions of existing debt.
SEC filing
Teva's Dutch finance subsidiaries plan euro and dollar notes due 2032 through 2037, with proceeds earmarked to redeem called notes and repay debt.
SEC filing
Luis Jodar joins as CMO and David McAvoy as CLO as Vaxcyte says VAX-31 Phase 3 topline data will arrive by end of October 2026 instead of the fourth quarter.
SEC filing